Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve 1. The Audited Standalone ....
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bliss GVS Pharma Ltd has informed exchanges about a Board meeting scheduled for May 12, 2026. The meeting will consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, along with the Statement of Assets and Liabilities and Cash Flow Statement. The Board will also consider recommending a final dividend for FY 2025-26. The filing notes that the Audit Report with modified opinion, if any, will be taken on record. The trading window for designated persons has been closed since April 1, 2026 and will remain closed till 48 hours after the results announcement.
This is a routine pre-result announcement intimation under SEBI regulations. The actual financial results and dividend recommendation will be disclosed after the Board meeting. Shareholders should await the official results for any material impact assessment.